{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:14:31Z","timestamp":1779804871921,"version":"3.53.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01239-6","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:49:54Z","timestamp":1778082594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High Concordance of Total Antibody and Transduction Inhibition Assays Enables Replacement of Cell-Based Antibody Testing for Preexisting Anti-AAV Immunity in Cynomolgus Monkey"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2073-0208","authenticated-orcid":false,"given":"Florian","family":"Neff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9007-9954","authenticated-orcid":false,"given":"Michael","family":"Antony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7628-6761","authenticated-orcid":false,"given":"Julia","family":"Merz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5514-0156","authenticated-orcid":false,"given":"Francesca","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5186-8657","authenticated-orcid":false,"given":"Uwe","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-183X","authenticated-orcid":false,"given":"Kay-Gunnar","family":"Stubenrauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1239_CR1","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1038\/mt.2010.175","volume":"18","author":"GD Hurlbut","year":"2010","unstructured":"Hurlbut GD, Ziegler RJ, Nietupski JB, Foley JW, Woodworth LA, Meyers E, et al. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther. 2010;18:1983\u201394.","journal-title":"Mol Ther"},{"key":"1239_CR2","doi-asserted-by":"crossref","unstructured":"Ail D, Dalkara D.\u00a0Preexisting neutralizing antibodies against different adeno-associated virus serotypes in humans and large animal models for gene therapy. Adv Exp Med Biol. 2023;1415:117\u201323.","DOI":"10.1007\/978-3-031-27681-1_18"},{"key":"1239_CR3","first-page":"471","volume":"26","author":"T Yang","year":"2022","unstructured":"Yang T, Braun M, Lembke W, McBlane F, Kamerud J, DeWall S, et al. Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper. Mol Ther. 2022;26:471\u201394.","journal-title":"Mol Ther"},{"key":"1239_CR4","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1089\/hum.2011.031","volume":"22","author":"L Wang","year":"2011","unstructured":"Wang L, Calcedo R, Bell P, Lin J, Grant RL, Siegel DL, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther. 2011;22:1389\u2013401.","journal-title":"Hum Gene Ther"},{"key":"1239_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.omtm.2022.01.011","volume":"24","author":"D Ail","year":"2022","unstructured":"Ail D, Ren D, Brazhnikova E, Nouvel-Jaillard C, Bertin S, Mirashrafi SB, et al. Systemic and local immune responses to intraocular AAV vector administration in non-human primates. Mol Ther - Methods Clin Dev. 2022;24:306\u201316.","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"1239_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/gt.2014.115","volume":"22","author":"MA Kotterman","year":"2015","unstructured":"Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV. Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther. 2015;22:116\u201326.","journal-title":"Gene Ther"},{"key":"1239_CR7","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0403-1","volume":"22","author":"B Gorovits","year":"2020","unstructured":"Gorovits B, Fiscella M, Havert M, Koren E, Long B, Milton M, et al. Recommendations for the development of cell-based anti-viral vector neutralizing antibody assays. AAPS J. 2020;22:24.","journal-title":"AAPS J"},{"key":"1239_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1080\/17576180.2024.2439229","volume":"17","author":"O Tounekti","year":"2025","unstructured":"Tounekti O, Prior S, Wassmer S, Xu J, Wong A, Fang X, et al. 2024 white paper on recent issues in bioanalysis: evolution of immunogenicity assessment beyond ADA\/NAb; regulated genomic\/NGS assays; hypersensitivity reactions; minimum noise reduction; false positive range; modernized vaccine approaches; NAb\/TAb correlation (part 3A \u2013 recommendations on advanced strategies for molecular assays and immunogenicity of gene therapy, cell therapy, vaccine; biotherapeutics immunogenicity assessment & clinical relevance part 3B \u2013 regulatory agencies\u2019 input on immunogenicity\/technologies of biotherapeutics, gene, cell & vaccine therapies). Bioanalysis. 2025;17:105\u201349.","journal-title":"Bioanalysis"},{"key":"1239_CR9","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-021-00628-3","volume":"23","author":"B Gorovits","year":"2021","unstructured":"Gorovits B, Azadeh M, Buchlis G, Harrison T, Havert M, Jawa V, et al. Evaluation of the humoral response to adeno-associated virus-based gene therapy modalities using total antibody assays. AAPS J. 2021;23:108.","journal-title":"AAPS J"},{"key":"1239_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/hgtb.2018.131","volume":"29","author":"U Kavita","year":"2018","unstructured":"Kavita U, Dai Y, Salvador L, Miller W, Adam LP, Levesque PC, et al. Development of a chemiluminescent ELISA method for the detection of total anti-adeno associated virus serotype 9 (AAV9) antibodies. Hum Gene Ther Methods. 2018;29:237\u201350.","journal-title":"Hum Gene Ther Methods"},{"key":"1239_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1208\/s12248-023-00805-6","volume":"25","author":"Y Dai","year":"2023","unstructured":"Dai Y, Dong H, Gleason C, Mora J, Kolaitis G, Balasubramanian N, et al. Comparison of pre-existing anti-AAV8 total antibody screening and confirmatory assays with a cell-based neutralizing assay in normal human serum. AAPS J. 2023;25:35.","journal-title":"AAPS J"},{"key":"1239_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101126","volume":"31","author":"Y Pan","year":"2023","unstructured":"Pan Y, Rohde M, Zeitler J, Namburi SVS, Cao L, Hu J, et al. A sensitive AAV transduction inhibition assay assists evaluation of critical factors for detection and concordance of pre-existing antibodies. Mol Ther Methods Clin Dev. 2023;31:101126.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1239_CR13","first-page":"199","volume":"24","author":"MR Gardner","year":"2022","unstructured":"Gardner MR, Mendes DE, Muniz CP, Martinez-Navio JM, Fuchs SP, Gao G, et al. High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes. Mol Ther. 2022;24:199\u2013206.","journal-title":"Mol Ther"},{"key":"1239_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4155\/bio-2023-0254","volume":"0","author":"U Wessels","year":"2024","unstructured":"Wessels U, Neff F, Fakhiri J, Mayer K, Brinkmann U, Stubenrauch K. Novel assay format for total anti-adeno-associated virus antibody detection with low capsid consumption and built-in specificity control. Bioanalysis. 2024;0:431\u201342.","journal-title":"Bioanalysis"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01239-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:59:28Z","timestamp":1779803968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01239-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1239"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01239-6","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal studies adhered to current ethical standards and applicable local and international regulations on animal experimentation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"F. Neff\u00a0is an employee of Hoffmann-La Roche Ltd, Basel. All other authors\u00a0are employees of Roche Diagnostics GmbH, Penzberg.\u00a0All authors are  owners of Roche shares.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"AI technology was used solely for the purposes of grammar checking, technical editing,\u00a0and language polishing to ensure clarity and professional tone.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"A.I. Disclosure"}}],"article-number":"94"}}